- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
3
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
3 companies
China Resources Pharmaceutical Group
Market Cap: HK$31.0b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.93
7D
0.8%
1Y
-8.2%
Essex Bio-Technology
Market Cap: HK$2.5b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$4.47
7D
1.1%
1Y
70.0%
JBM (Healthcare)
Market Cap: HK$2.3b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.85
7D
-0.3%
1Y
120.9%